InflaRx

IFRXPhase 3

Jena, GermanyFounded 2007inflarx.de

InflaRx is a clinical-stage biopharma focused on selectively inhibiting the C5a/C5aR pathway of the complement system, a key driver of inflammatory diseases. The company achieved a significant milestone with the FDA EUA for vilobelimab in severe COVID-19 and is developing this candidate and its oral C5aR inhibitor, izicopan, across multiple dermatologic and critical care indications. Despite recent clinical setbacks, InflaRx continues to explore the therapeutic potential of its complement platform in life-threatening and debilitating inflammatory conditions.

Market Cap

$63.7M

Founded

2007

Focus

AntibodiesBiologics

IFRX · Stock Price

USD 0.941.57 (-62.55%)

Historical price data

AI Company Overview

Technology Platform

Proprietary platform for developing highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR, designed to control harmful inflammation while preserving parts of the immune system's protective function.

Pipeline Snapshot

15 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
vilobelimab + Placebo	Pyoderma Gangrenosum	Phase 3
IFX-1 + BSC + BSC + IFX-1 + SOC + Placebo + SOC	Severe COVID-19 Pneumonia	Phase 2/3
Cohort C: bevacizumab + Cohort C: placebo	Acute Respiratory Distress Syndrome (ARDS)	Phase 2
IFX-1 + Placebo	Systemic Inflammatory Response Syndrome	Phase 2
vilobelimab	Pyoderma Gangrenosum	Phase 2

Funding History

Total raised: $100M

IPO$60MUndisclosedNov 9, 2017

Series B$30MMPM CapitalJun 15, 2015

Series A$10MMPM CapitalJun 15, 2013

Opportunities

The oral C5aR inhibitor izicopan represents a major growth opportunity in large chronic inflammatory markets like hidradenitis suppurativa and chronic spontaneous urticaria, where an oral therapy could be highly differentiated.

Exploring vilobelimab in broader ARDS and partnering its EU rights in Europe could provide near-term value inflection points.

Risk Factors

Key risks include clinical failure of lead pipeline candidates, financial instability due to low stock price and cash burn, and the limited, pandemic-dependent commercial potential of the COVID-19 EUA.

The company faces significant competition in the complement inhibitor space.

Competitive Landscape

InflaRx competes with large pharma (AstraZeneca/Alexion, Roche) and biotechs (Apellis, ChemoCentryx) in the complement space. Its differentiation is selective C5a inhibition, but it must prove clinical advantages over broader C5 inhibitors and established anti-inflammatory therapies in each target indication.